

*DB=PGPB, USPT; PLUR=YES; OP=ADJ*

L5 (cd40L or cd40 adj ligand or gp39 or 5c8) same (cd20) same (leukem\$ or lymphoma\$) 13 L5

L4 (cd40L or cd40 adj ligand or gp39 or 5c8) and (cd20) and (leukem\$ or lymphoma\$) 487 L4

L3 L2 and (leukem\$ or lymphoma\$) 17 L3

L2 L1 and (cd40L or cd40 adj ligand or gp39 or 5c8) and (cd20) 17 L2

L1 hanna.in.

09/435992

**Search Results - Record(s) 1 through 10 of 13 returned.**

---

1. [20040018522](#). 06 May 03. 29 Jan 04. Identification of dysregulated genes in patients with multiple sclerosis. Dangond, Fernando, et al. 435/6; 702/20 C12Q001/68 G06F019/00 G01N033/48 G01N033/50.

---

2. [20040010810](#). 04 Jun 03. 15 Jan 04. Generation of xenogeneic antibodies. Kucherlapati, Raju, et al. 800/6; 530/388.15 C12P021/08 C07K016/00 A01K067/027.

---

3. [20040009479](#). 24 Apr 02. 15 Jan 04. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases. Wohlgemuth, Jay, et al. 435/6; C12Q001/68.

---

4. [20030219433](#). 14 Feb 03. 27 Nov 03. Anti-CD20 antibodies and fusion proteins thereof and methods of use. Hansen, Hans, et al. 424/141.1; 530/388.15 A61K039/395 C07K016/44.

---

5. [20030211107](#). 12 Sep 02. 13 Nov 03. Use of CD23 antagonists for the treatment of neoplastic disorders. Hariharan, Kandasamy, et al. 424/155.1; 435/7.23 514/12 G01N033/574 A61K039/395 A61K038/17.

---

6. [20030204090](#). 13 Mar 03. 30 Oct 03. Indolizine compounds. Ono, Mitsunori, et al. 546/138; C07D455/02.

---

7. [20030180292](#). 14 Mar 02. 25 Sep 03. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/141.1; 424/1.49 424/144.1 514/105 514/251 514/263.1 514/34 A61K051/00 A61K039/395 A61K031/525 A61K031/52.

---

8. [20030103971](#). 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.

---

9. [20020172677](#). 03 Apr 01. 21 Nov 02. Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies. Lahn, Michael F., et al. 424/145.1; 424/43 A61K039/395 A61K009/00.

---

10. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.

---

[Generate Collection](#)

[Print](#)

| Term   | Documents |
|--------|-----------|
| CD40L  | 1406      |
| CD40LS | 3         |
| CD40   | 3448      |
| CD40S  | 0         |
| LIGAND | 72582     |

|   |       |
|---|-------|
| LIGANDS   | 59509 |
| GP39  | 326   |
| GP39S   | 0     |
| 5C8   | 112   |
| 5C8S  | 0     |
| CD20  | 1849  |
| ((CD40L OR CD40 ADJ LIGAND OR GP39 OR 5C8) SAME<br>(CD20) SAME (LEUKEM\$ OR LYMPHOMA\$)).PGPB,USPT. | 13    |

[There are more results than shown above. Click here to view the entire set.](#)

[Prev](#)

returned.

---

- 11. 20020009444. 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.

---
- 12. 20020006404. 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.

---
- 13. 20010018041. 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.

---

[Generate Collection](#)

[Print](#)